Human Oncology & Pathogenesis Program
The Jedd Wolchok Lab
Research
Professor
The overall goals of my laboratory efforts are to develop and implement new ways to use the immune system to treat cancer.
Some of our ongoing projects include:
- Investigation of the GITR pathway as it relates to regulatory and effector T cells.
- Use of OX40 agonists alone and in combination with chemotherapy.
- Exploration of the role of myeloid derived suppressor cells in tumor immunity.
- Studying of the mechanisms underlying coordinated regulation of myeloid cells and IDO in the tumor environment and their therapeutic relevance.
- Role of CD47 in T cell signaling.
- Developing optimal cancer vaccine strategies in pre-clinical mouse models.
- Role of exercise in immune checkpoint blockade.
We are also closely aligned with the Ludwig Center for Cancer Immunity and work closely with that group to monitor immune responses in patients receiving experimental immunotherapy treatments.
Featured News
People
Jedd D. Wolchok, MD, PhD, FASCO
Chief, Immuno-Oncology Service, Human Oncology and Pathogenesis Program
Professor
- Physician-scientist Jedd Wolchok investigates novel approaches for cancer immunotherapy and mechanisms of tumor cell–immune cell interactions. He has been at the forefront of cancer immunotherapy, as an active clinician scientist exploring innovative immunotherapeutic strategies in laboratory models and as a principal investigator in numerous pivotal clinical trials.
- Princeton University, Princeton, NJ BA
- New York University, New York, NY MS
- New York University, New York, NY PhD
- New York University, New York, NY MD
- View physician profile
- Physician profile
Members
Lab Head
Attending Biologist
Research Lab Manager
Senior Research Scientist
Research Associate
PICI Bridge Scholar
Research Associate
Research Associate
Research Fellow
Research Fellow
Research Fellow
Bioinformatics Technician
Senior Research Assistant
Senior Research Assistant
Senior Research Technician
Senior Research Technician
Research Technician
Research Technician
PhD Graduate Student
PhD Graduate Student
Assistant Attending Physician
Assistant Member
Research Technician
Assistant Attending Physician
Medical Oncologist
Neuro-Oncologist
Medical Oncologist
Hematologic Oncologist
Medical Oncology Fellow
Medical Oncology Fellow
Graduate Research Assistant
Research Fellow
Research Technician
Senior Research Technician
Research Associate
Research Fellow
Project Coordinator
Research Fellow
Graduate Student
Senior Research Technician
Lab Alumni
Immunotherapy Program Manager
Senior Research Scientist
Research Associate
Research Fellow
Research Fellow
Graduate Student
Graduate Student
Research Technician
Research Technician
Senior Research Assistant
Research Technician
Research Technician
Research Technician
Research Technician
Research Technician
Research Technician
Assistant Attending, Department of Medicine
Research Technician
Research Technician
Medical Oncologist
Research Laboratory Manager
Assistant Member
Research Fellow
Visiting Investigator
Administrative Assistant
Fulbright Scholar
Research Assistant
Research Technician
Senior Research Technician
Research Assistant
Senior Research Technician
Senior Research Technician
Graduate Research Assistant
Research Fellow
Research Technician
Medical Oncology Fellow
Research Fellow
Research Assistant
Bioinformatics Engineer IV
Research Technician
Research Technician
Visiting Investigator
Research Technician
Research Technician
Lab Affiliations
Achievements
- The use of immunomodulatory antibodies, specifically antibodies which interfere with the CTLA-4 co-inhibitory pathway has been studied in over a dozen clinical trials. Dr. Wolchok led a phase III study of ipilimumab plus dacarbazine in patients with previously untreated metastatic melanoma. Overall survival was significantly longer in the group receiving ipilimumab plus dacarbazine than in the group receiving dacarbazine plus placebo (Wolchok et al, NEJM 30;364(26):2517-26, 2011)
